Institute for Personalized Respiratory Medicine, Section of Pulmonary, Critical Care, Sleep, and Allergy, University of Illinois at Chicago, Chicago, Illinois.
Am J Respir Cell Mol Biol. 2014 Feb;50(2):328-36. doi: 10.1165/rcmb.2013-0058OC.
The statins are now recognized to have pleiotropic properties, including augmentation of endothelial barrier function. To explore the mechanisms involved, we investigated the effect of simvastatin on endothelial cell (EC) tight junctions. Western blotting of human pulmonary artery ECs treated with simvastatin (5 μM) confirmed a significant time-dependent increase (16-48 h) in claudin-5 protein expression compared with controls, without detectable alterations in zonula occludens-1 or occludin. These effects were associated with membrane translocation of VE-cadherin, whereas translocation of vascular endothelial cadherin (VE-cadherin; silencing RNA) inhibited simvastatin-induced claudin-5 up-regulation. Moreover, simvastatin treatment of ECs induced increased phosphorylation of both FoxO1 and β-catenin, transcriptional regulators of claudin-5 expression mediated by VE-cadherin. Subsequently, we found no effect of claudin-5 silencing on EC barrier protection by simvastatin in response to thrombin stimulation, as measured by either transendothelial electrical resistance or by EC monolayer flux of FITC-dextran (2,000 kD). However, silencing of claudin-5 did significantly attenuate simvastatin-mediated EC barrier protection in response to thrombin, as measured by monolayer flux of sodium fluorescein (376 Da). Finally, employing a murine model of LPS-induced acute lung injury, there was no effect of claudin-5 silencing in vivo (intratracheal injection) on bronchoalveolar lavage fluid protein or cell counts, but LPS-induced lung tissue extravasation of the small molecular weight markers, sodium fluorescein and Hochst stain (562 Da), were significantly increased in claudin-5-silenced animals compared with simvastatin-treated control animals. These findings implicate a distinct mechanism underlying size-selective endothelial barrier-protective properties of statins, and may ultimately lead to new novel therapeutic targets for patients with acute lung injury.
他汀类药物现在被认为具有多效性,包括增强内皮屏障功能。为了探索相关机制,我们研究了辛伐他汀对人肺动脉内皮细胞(EC)紧密连接的影响。用辛伐他汀(5 μM)处理人肺动脉内皮细胞后,通过 Western blot 证实 Claudin-5 蛋白表达明显呈时间依赖性增加(16-48 小时),而封闭蛋白-1(zonula occludens-1)或紧密连接蛋白-1(occludin)没有明显变化。这些作用与 VE-钙黏蛋白的膜转位有关,而血管内皮钙黏蛋白(VE-cadherin;沉默 RNA)的转位则抑制了辛伐他汀诱导的 Claudin-5 上调。此外,辛伐他汀处理内皮细胞后,FoxO1 和 β-连环蛋白的磷酸化均增加,这两种蛋白均为 VE-钙黏蛋白介导的 Claudin-5 表达的转录调节因子。随后,我们发现 Claudin-5 沉默对凝血酶刺激引起的内皮细胞屏障保护作用没有影响,这一结果通过跨内皮电阻或 FITC-葡聚糖(2000 kD)的内皮单层通量来测量。然而,Claudin-5 沉默显著减弱了辛伐他汀对凝血酶刺激的内皮细胞屏障保护作用,这一结果通过 376 Da 的荧光素钠的单层通量来测量。最后,在 LPS 诱导的急性肺损伤的小鼠模型中,Claudin-5 沉默(气管内注射)对内支气管肺泡灌洗液蛋白或细胞计数没有影响,但 LPS 诱导的肺组织小分子标志物,如荧光素钠和 Hoechst 染色(562 Da)的外渗,在 Claudin-5 沉默的动物中明显增加,而在辛伐他汀治疗的对照动物中则没有。这些发现提示了他汀类药物具有选择性内皮屏障保护作用的独特机制,这可能为急性肺损伤患者提供新的治疗靶点。